Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,222.50 +12.50 (+0.30%) Dow Futures
33,362.00 +102.00 (+0.31%) Nasdaq Futures
13,451.00 +59.00 (+0.44%) Russell 2000 Futures
1,976.20 +6.70 (+0.34%) Crude Oil
91.79 -0.14 (-0.15%) Gold
1,802.20 -11.50 (-0.63%)
Antibe Therapeutics Inc. (ATBPF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 01:42PM EDT
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.5000 |
| Open | 0.4840 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4660 - 0.5022 |
| 52 Week Range | 0.4190 - 1.1400 |
| Volume | |
| Avg. Volume | 4,903 |
| Market Cap | 25.602M |
| Beta (5Y Monthly) | -0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4130 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.49 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Subscribe to Yahoo Finance Plus to view Fair Value for ATBPF
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- ANTIBE THERAPEUTICS INCAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat2 days agoMorningstar
- Zacks Small Cap Research
ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22 Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base
- Simply Wall St.
Will Antibe Therapeutics (TSE:ATE) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Business Wire
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
TORONTO, June 30, 2022--Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
